Entertainment Source-linked briefing

Indapta Therapeutics Announces Oral Presentation of Clinical Proof-of-Concept Data for IDP-023 Allogeneic g-NK Cell Therapy Plus Isatuximab in Heavily Pretreated Multiple Myeloma at 2026 Annual Meeting of Society for Immunotherapy of Cancer

HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta’s IDP-023 g-NK cell therapy plus isatuximab achieved a 45% response rate in daratumumab-refractory multiple myeloma, presented at SITC 2026.

Businesswire Health Desk

Original contributor via Businesswire

| November 6, 2026 | 1 min read | Updated Nov 7, 2:00 AM

HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta’s IDP-023 g-NK cell therapy plus isatuximab achieved a 45% response rate in daratumumab-refractory multiple myeloma, presented at SITC 2026.

Source disclosure

This is a source-linked briefing. Read the original report from Businesswire .

Health Businesswire